Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

The haemophilia drug market

Nature Reviews Drug Discovery volume 17, pages 541–542 (2018)Cite this article

Subjects

Haemophilia is classified as severe, moderate or mild, depending on the patient's residual plasma levels of clotting factor. There are ~39,000 patients with haemophilia A (approximately 40% severe) and ~10,000 patients with haemophilia B (approximately 30% severe) across the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) plus the United States.

The drug market for haemophila is undergoing major changes, owing to advances in gene therapy and protein engineering and to novel strategies that target negative clotting regulators.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Current sales and 2027 market forecast for the haemophilia market.

Author information

Authors and Affiliations

  1. Decision Resources Group, London, UK

    Kerri Brown & Graeme Green

Authors
  1. Kerri Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Graeme Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Graeme Green.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brown, K., Green, G. The haemophilia drug market. Nat Rev Drug Discov 17, 541–542 (2018). https://doi.org/10.1038/nrd.2018.54

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.54

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research